IGC Pharma (IGC) Price & Analysis

Compare

958 Followers

IGC Stock Chart & Stats

$0.40

>-$0.01(-2.38%)

At close: Jan 08 4:00 PM EST

$0.40

>-$0.01(-2.38%)

Day’s Range― - ―

52-Week Range$0.25 - $0.50

Previous CloseN/A

Volume646.33K

Average Volume (3M)711.34K

Market Cap

$36.89M

Enterprise Value$22.89M

Total Cash (Recent Filing)$454.00K

Total Debt (Recent Filing)$202.00K

Price to Earnings (P/E)―

Beta0.40

Next Earnings

Nov 12, 2025

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding91,959,114

10 Day Avg. Volume800,446

30 Day Avg. Volume711,341

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.62

Enterprise Value/Revenue17.25

Enterprise Value/Gross Profit37.52

Enterprise Value/Ebitda-3.60

Forecast

1Y Price Target

$4.50

Price Target Upside1025.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsIGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.

Growth OpportunitiesThe company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.

Market PotentialThe large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.

Bears Say

Market RisksThe large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.

IGC Pharma News

IGC Pharma expands Phase 2 CALMA trial to University of South Florida

IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 CALMA clinical trial evaluating investigational drug candidate...

6d ago

IGC

IGC Pharma announces in-vitro preclinical data for IGC-1C

IGC Pharma (IGC) announced in-vitro findings for IGC-1C, a low-molecular weight compound. The data are consistent with IGC-1C...

13d ago

IGC

IGC Pharma expands CALMA Phase 2 trial with Ichor Research site

IGC Pharma (IGC) announced the addition of a new clinical trial site to its ongoing Phase 2 study...

21d ago

IGC

Tilray up after Trump posts video on medical benefits of CBD for seniors

Tilray (TLRY) is up 17.5% in premarket trading after President Donald Trump posted a video on social media...

21d ago

ACB

CGC

IGC Pharma reports 50% patient enrollment milestone in Phase 2 CALMA trial

IGC Pharma (IGC) reached a key enrollment milestone of 50% for its ongoing Phase 2 CALMA clinical trial...

28d ago

IGC

IGC Pharma Subsidiary Signs Asset Sale Agreement

IGC Pharma ( ($IGC) ) has provided an announcement. On September 29, 2025, IGC Pharma‘s subsidiary, Holi Hemp...

19d ago

IGC

IGC Pharma expands CALMA Phase 2 trial with Royal Jubilee Hospital

IGC Pharma (IGC) announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment...

2M ago

IGC

IGC Pharma receives notice of allowance for THC microdose-based treatment

IGC Pharma (IGC) received a Notice of Allowance from the United States Patent and Trademark Office for its...

2M ago

IGC

IGC Pharma expands CALMA Phase 2 trial with Lynn Health Science Institute site

IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug...

2M ago

IGC

IGC Pharma reports Q1 EPS (2c) vs. (3c) last year

Reports revenue $328,000 vs. $272,000 last year. Ram Mukunda, CEO of IGC Pharma (IGC), commented, “We began fiscal...

2M ago

IGC

Igc Pharma’s Risky Venture: Navigating Financial Instability Amid Bitcoin Investment Plans

Igc Pharma, Inc. (IGC) has disclosed a new risk, in the Debt & Financing category. Igc Pharma, Inc....

2M ago

IGC

IGC Pharma highlights preclinical data on IGC-M3

IGC Pharma (IGC) announced preclinical results for IGC-M3, a novel small molecule designed to address multiple biological drivers...

2M ago

IGC

IGC Pharma Reports Transformative Year in Alzheimer’s Innovation

India Globalization Capital ( ($IGC) ) has released its Q4 earnings. Here is a breakdown of the information...

4M ago

IGC

Options Volatility and Implied Earnings Moves Today, June 30, 2025

Today, several major companies are expected to report earnings: IGC Pharma (IGC), Progress Software (PRGS). Ahead of earnings,...

4M ago

IGC

PRGS

IGC FAQ

What was IGC Pharma’s price range in the past 12 months?

IGC Pharma lowest stock price was $0.25 and its highest was $0.50 in the past 12 months.

What is IGC Pharma’s market cap?

IGC Pharma’s market cap is $36.89M.

When is IGC Pharma’s upcoming earnings report date?

IGC Pharma’s upcoming earnings report date is Nov 12, 2025 which is in 23 days.

How were IGC Pharma’s earnings last quarter?

Currently, no data Available

Is IGC Pharma overvalued?

According to Wall Street analysts IGC Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does IGC Pharma pay dividends?

IGC Pharma does not currently pay dividends.

What is IGC Pharma’s EPS estimate?

IGC Pharma’s EPS estimate is -0.02.

How many shares outstanding does IGC Pharma have?

IGC Pharma has 91,959,114 shares outstanding.

What happened to IGC Pharma’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of IGC Pharma?

Currently, no hedge funds are holding shares in IGC

IGC Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-90.87%

Trailing 12-Months

Asset Growth

-25.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

IGC Pharma

IGC Pharma (IGC) is a biopharmaceutical company focused on developing innovative therapies for the treatment of chronic pain and neurological disorders. The company operates primarily in the pharmaceutical and biotechnology sectors, leveraging its proprietary formulations and technologies to create novel medicinal products. IGC’s core offerings include cannabinoid-based therapeutics that aim to address unmet medical needs, particularly in areas such as pain management and behavioral health.

IGC Pharma (IGC) Earnings & Revenues

Historic Earnings Reports

IGC Earnings Call

Q4 2025

0:00 / 0:00

IGC Stock 12 Month Forecast

Average Price Target

$4.50

▲(1025.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.66,0.98,1.3,1.62,1.9400000000000002,2.26,2.58,2.9,3.2199999999999998,3.54,3.86,4.18,{"y":4.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.66,0.98,1.3,1.62,1.9400000000000002,2.26,2.58,2.9,3.2199999999999998,3.54,3.86,4.18,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.66,0.98,1.3,1.62,1.9400000000000002,2.26,2.58,2.9,3.2199999999999998,3.54,3.86,4.18,{"y":4.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.29,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.32,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.28,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.29,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.29,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.38,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.3,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >